Overview of fibrillar and oligomeric assemblies of amyloidogenic proteins

Non-fibrillar Amyloidogenic Protein Assemblies - Common Cytotoxins Underlying Degenerative Diseases

Volumn 9789400727748, Issue , 2012, Pages 1-36

  Rahimi, Farid ^a   Bitan, Gal ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid; Amyloid fibrils; Cytotoxicity; Degeneration; Oligomer; Protein misfolding

Indexed keywords

EID: 84931376095     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-2774-8_1     Document Type: Chapter

References (378)

1. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A (2000) Mice lacking a-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239-252
2. Adamczyk A, Strosznajder JB (2006) a-Synuclein potentiates Ca 2+ influx through voltagedependent Ca 2+ channels. Neuroreport 17:1883-1886
3. Aguzzi A, Calella AM (2009) Prions: protein aggregation and infectious diseases. Physiol Rev 89:1105-1152
4. Aguzzi A, O'Connor T (2010) Protein aggregation diseases: pathogenicity and therapeutic p erspectives. Nat Rev Drug Discov 9:237-248
5. Ahmad A, Uversky VN, Hong D, Fink AL (2005) Early events in the fibrillation of monomeric insulin. J Biol Chem 280:42669-42675
6. Ahmad R, Rasheed Z, Ahsan H (2009) Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol Immunotoxicol 31:388-396
7. Aksenov MY, Aksenova MV, Butterfield DA, Hensley K, Vigo-Pelfrey C, Carney JM (1996) Glutamine synthetase-induced enhancement of b-amyloid peptide A b (1-40) neurotoxicity accompanied by abrogation of fibril formation and A b fragmentation. J Neurochem 66: 2050-2056
8. Alarcon JM, Brito JA, Hermosilla T, Atwater I, Mears D, Rojas E (2006) Ion channel formation by Alzheimer's disease amyloid b-peptide (A b 40) in unilamellar liposomes is determined by anionic phospholipids. Peptides 27:95-104
9. Alexandrescu AT (2005) Amyloid accomplices and enforcers. Protein Sci 14:1-12
10. Anguiano M, Nowak RJ, Lansbury PT Jr (2002) Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41:11338-11343
11. Arispe N, Pollard HB, Rojas E (1993a) Giant multilevel cation channels formed by Alzheimer disease amyloid b-protein [A b P-(1-40)] in bilayer membranes. Proc Natl Acad Sci USA 90:10573-10577
12. Arispe N, Rojas E, Pollard HB (1993b) Alzheimer disease amyloid b protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 90:567-571
13. Ashe KH, Zahs KR (2010) Probing the biology of Alzheimer's disease in mice. Neuron 66:631-645
14. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of a-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295:865-868
15. Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B (2010) Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans 38:493-497
16. Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, Chiti F, Dobson CM, Stefani M (2006) Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci 26:8160-8167
17. Bahadi R, Farrelly PV, Kenna BL, Curtain CC, Masters CL, Cappai R, Barnham KJ, Kourie JI (2003) Cu 2+-induced modification of the kinetics of A b (1-42) channels. Am J Physiol Cell Physiol 285:C873-C880
18. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H (2005) Globular amyloid b-peptide oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95:834-847
19. Barsoum SC, Callahan HM, Robinson K, Chang PL (2000) Canine models for human genetic neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 24:811-823
20. Bauer PO, Nukina N (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 110:1737-1765
21. Bauer HH, Aebi U, Haner M, Hermann R, Muller M, Merkle HP (1995) Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin. J Struct Biol 115:1-15
22. Bellotti V, Nuvolone M, Giorgetti S, Obici L, Palladini G, Russo P, Lavatelli F, Perfetti V, Merlini G (2007) The workings of the amyloid diseases. Ann Med 39:200-207
23. Benvenga S, Facchiano A (1995) Atrial natriuretic peptide and amyloidosis. J Intern Med 237:525-526
24. Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA (2003) Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-b structure. Proc Natl Acad Sci USA 100:9034-9038
25. Bertrand E, Lechowicz W, Lewandowska E, Szpak GM, Dymecki J, Kosno-Kruszewska E, Wierzba-Bobrowicz T (2003) Degenerative axonal changes in the hippocampus and amygdala in Parkinson's disease. Folia Neuropathol 41:197-207
26. Betarbet R, Sherer TB, Greenamyre JT (2005) Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol 191(Suppl 1):S17-S27
27. Bhatia R, Lin H, Lal R (2000) Fresh and globular amyloid b protein (1-42) induces rapid cellular degeneration: evidence for A b P channel-mediated cellular toxicity. FASEB J 14:1233-1243
28. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB (2003a) Amyloid b-protein (A b ) assembly: A b 40 and A b 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100:330-335
29. Bitan G, Tarus B, Vollers SS, Lashuel HA, Condron MM, Straub JE, Teplow DB (2003b) A molecular switch in amyloid assembly: Met35 and amyloid b-protein oligomerization. J Am Chem Soc 125:15359-15365
30. Bitan G, Vollers SS, Teplow DB (2003c) Elucidation of primary structure elements controlling early amyloid b-protein oligomerization. J Biol Chem 278:34882-34889
31. Bitan G, Fradinger EA, Spring SM, Teplow DB (2005) Neurotoxic protein oligomers-what you see is not always what you get. Amyloid 12:88-95
32. Boeve BF (2007) Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and amyotrophic lateral sclerosis. Alzheimer Dis Assoc Disord 21:S31-S38
33. Botella JA, Bayersdorfer F, Gmeiner F, Schneuwly S (2009) Modelling Parkinson's disease in Drosophila. Neuromolecular Med 11:268-280
34. Braun S, Humphreys C, Fraser E, Brancale A, Bochtler M, Dale TC (2011) Amyloid-associated nucleic acid hybridisation. PLoS One 6:e19125
35. Bucciantini M, Calloni G, Chiti F, Formigli L, Nosi D, Dobson CM, Stefani M (2004) Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 279: 31374-31382
36. Bucciantini M, Rigacci S, Berti A, Pieri L, Cecchi C, Nosi D, Formigli L, Chiti F, Stefani M (2005) Patterns of cell death triggered in two different cell lines by HypF-N prefibrillar aggregates. FASEB J 19:437-439
37. Bunka DH, Mantle BJ, Morten IJ, Tennent GA, Radford SE, Stockley PG (2007) Production and characterization of RNA aptamers specific for amyloid fibril epitopes. J Biol Chem 282:34500-34509
38. Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC (2010) a-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329:1663-1667
39. Butterfield DA, Bader Lange ML, Sultana R (2010) Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta 1801:924-929
40. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, Relini A, Stefani M, Dobson CM, Cecchi C, Chiti F (2010) A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol 6:140-147
41. Canale C, Torrassa S, Rispoli P, Relini A, Rolandi R, Bucciantini M, Stefani M, Gliozzi A (2006) Natively folded HypF-N and its early amyloid aggregates interact with phospholipid monolayers and destabilize supported phospholipid bilayers. Biophys J 91:4575-4588
42. Cardoso F (2009) Huntington disease and other choreas. Neurol Clin 27:719-736, vi
43. Carulla N, Caddy GL, Hall DR, Zurdo J, Gairi M, Feliz M, Giralt E, Robinson CV, Dobson CM (2005) Molecular recycling within amyloid fibrils. Nature 436:554-558
44. Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:267-298
45. Cecchi C, Pensalfini A, Baglioni S, Fiorillo C, Caporale R, Formigli L, Liguri G, Stefani M (2006) Differing molecular mechanisms appear to underlie early toxicity of prefibrillar HypF-N aggregates to different cell types. FEBS J 273:2206-2222
46. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, Sudhof TC (2004) Double-knockout mice for a-and b-synucleins: effect on synaptic functions. Proc Natl Acad Sci USA 101:14966-14971
47. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC (2005) a-Synuclein cooperates with CSP a in preventing neurodegeneration. Cell 123:383-396
48. Chen S, Berthelier V, Hamilton JB, O'Nuallain B, Wetzel R (2002) Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 41:7391-7399
49. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333-366
50. Chiti F, Webster P, Taddei N, Clark A, Stefani M, Ramponi G, Dobson CM (1999) Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 96:3590-3594
51. Chiti F, Bucciantini M, Capanni C, Taddei N, Dobson CM, Stefani M (2001) Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N-terminal domain. Protein Sci 10:2541-2547
52. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL (2003) Self-assembly of A b (1-42) into globular neurotoxins. Biochemistry 42:12749-12760
53. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC (1988) Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151-159
54. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-b protein specifically disrupt cognitive function. Nat Neurosci 8:79-84
55. Cohen AS, Calkins E (1959) Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 183:1202-1203
56. Cohen AS, Calkins E (1964) The isolation of amyloid fibrils and a study of the effect of collagenase and hyaluronidase. J Cell Biol 21:481-486
57. Comenzo RL (2006) Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma 7:182-185
58. Comenzo RL (2007) Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw 5:179-187
59. Conway KA, Harper JD, Lansbury PT Jr (2000a) Fibrils formed in vitro from a-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39:2552-2563
60. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr (2000b) Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97:571-576
61. Cowan CM, Chee F, Shepherd D, Mudher A (2010) Disruption of neuronal function by soluble hyperphosphorylated tau in a Drosophila model of tauopathy. Biochem Soc Trans 38:564-570
62. Cozzolino M, Ferri A, Carri MT (2008) Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid Redox Signal 10:405-443
63. Cozzolino M, Pesaresi MG, Amori I, Crosio C, Ferri A, Nencini M, Carri MT (2009) Oligomerization of mutant SOD1 in mitochondria of motoneuronal cells drives mitochondrial damage and cell toxicity. Antioxid Redox Signal 11:1547-1558
64. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De Pooter T, Mattheijssens M, Van den Broeck M, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S, Van Broeckhoven C (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920-924
65. Cruz L, Urbanc B, Borreguero JM, Lazo ND, Teplow DB, Stanley HE (2005) Solvent and mutation effects on the nucleation of amyloid b-protein folding. Proc Natl Acad Sci USA 102:18258-18263
66. Dawson TM (2007) Unraveling the role of defective genes in Parkinson's disease. Parkinsonism Relat Disord 13(Suppl 3):S248-S249
67. Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson's disease. Neuron 66:646-661
68. De Felice FG, Vieira MN, Meirelles MN, Morozova-Roche LA, Dobson CM, Ferreira ST (2004) Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure. FASEB J 18:1099-1101
69. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) A b oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptordependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590-11601
70. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL (2008) Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A b oligomers. Neurobiol Aging 29:1334-1347
71. Dember LM, Jaber BL (2006) Dialysis-related amyloidosis: late finding or hidden epidemic? Semin Dial 19:105-109
72. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280:17294-17300
73. Di Pasquale E, Fantini J, Chahinian H, Maresca M, Taieb N, Yahi N (2010) Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of a-synuclein is corrected by GM3 but not by GM1 gangliosides. J Mol Biol 397:202-218
74. Dickson DW (2009) Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol 3:1-23
75. Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr (2002) Annular a-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41:10209-10217
76. Dobson CM (2001) The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci 356:133-145
77. Dobson CM (2004) Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol 15:3-16
78. Double KL, Reyes S, Werry EL, Halliday GM (2010) Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol 92:316-329
79. Dyson HJ, Wright PE (2005) Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 6:197-208
80. Dzwolak W, Loksztejn A, Smirnovas V (2006) New insights into the self-assembly of insulin amyloid fibrils: an H-D exchange FT-IR study. Biochemistry 45:8143-8151
81. Dzwolak W, Loksztejn A, Galinska-Rakoczy A, Adachi R, Goto Y, Rupnicki L (2007) Conformational indeterminism in protein misfolding: chiral amplification on amyloidogenic pathway of insulin. J Am Chem Soc 129:7517-7522
82. Eanes ED, Glenner GG (1968) X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 16:673-677
83. Eisen A (2009) Amyotrophic lateral sclerosis: A 40-year personal perspective. J Clin Neurosci 16:505-512
84. Eisenberg D, Nelson R, Sawaya MR, Balbirnie M, Sambashivan S, Ivanova MI, Madsen AO, Riekel C (2006) The structural biology of protein aggregation diseases: fundamental questions and some answers. Acc Chem Res 39:568-575
85. Elder GA, Gama Sosa MA, De Gasperi R (2010) Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med 77:69-81
86. Eshaghian S, Kaul S, Shah PK (2007) Cardiac amyloidosis: new insights into diagnosis and management. Rev Cardiovasc Med 8:189-199
87. Feng LR, Federoff HJ, Vicini S, Maguire-Zeiss KA (2010) a-Synuclein mediates alterations in membrane conductance: A potential role for a-synuclein oligomers in cell vulnerability. Eur J Neurosci 32:10-17
88. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L (2004) Prediction of sequencedependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 22:1302-1306
89. Ferreira ST, Vieira MN, De Felice FG (2007) Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59:332-345
90. Fezoui Y, Teplow DB (2002) Kinetic studies of amyloid b-protein fibril assembly. Differential effects of a-helix stabilization. J Biol Chem 277:36948-36954
91. Fezoui Y, Hartley DM, Walsh DM, Selkoe DJ, Osterhout JJ, Teplow DB (2000) A de novo designed helix-turn-helix peptide forms nontoxic amyloid fibrils. Nat Struct Biol 7:1095-1099
92. Flood DG, Lin YG, Lang DM, Trusko SP, Hirsch JD, Savage MJ, Scott RW, Howland DS (2009) A transgenic rat model of Alzheimer's disease with extracellular A b deposition. Neurobiol Aging 30:1078-1090
93. Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, Lansbury PT Jr (2007) The impact of the E46K mutation on the properties of a-synuclein in its monomeric and oligomeric states. Biochemistry 46:7107-7118
94. Freir DB, Fedriani R, Scully D, Smith IM, Selkoe DJ, Walsh DM, Regan CM (2011) A b oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging 32: 2211-2218
95. Frid P, Anisimov SV, Popovic N (2007) Congo red and protein aggregation in neurodegenerative diseases. Brain Res Rev 53:135-160
96. Frieden C (2007) Protein aggregation processes: in search of the mechanism. Protein Sci 16:2334-2344
97. Friedreich N, Kekulé FA (1859) Zur Amyloidfrage. Virchows Arch Pathol Anat Physiol XVI:50-65
98. Frost B, Diamond MI (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11:155-159
99. Gaspar RC, Villarreal SA, Bowles N, Hepler RW, Joyce JG, Shughrue PJ (2010) Oligomers of b-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model. Exp Neurol 223:394-400
100. Gasser T (2009) Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 11:e22
101. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 102:2273-2276
102. George JM, Jin H, Woods WS, Clayton DF (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15:361-372
103. Georgieva ER, Ramlall TF, Borbat PP, Freed JH, Eliezer D (2008) Membrane-bound a-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. J Am Chem Soc 130:12856-12857
104. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA (1998) Aging renders the brain vulnerable to amyloid b-protein neurotoxicity. Nat Med 4:827-831
105. Gharibyan AL, Zamotin V, Yanamandra K, Moskaleva OS, Margulis BA, Kostanyan IA, Morozova-Roche LA (2007) Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J Mol Biol 365:1337-1349
106. Giannetti AM, Lindwall G, Chau MF, Radeke MJ, Feinstein SC, Kohlstaedt LA (2000) Fibers of tau fragments, but not full length tau, exhibit a cross b-structure: implications for the formation of paired helical filaments. Protein Sci 9:2427-2435
107. Ginsberg SD, Galvin JE, Chiu TS, Lee VM, Masliah E, Trojanowski JQ (1998) RNA sequestration to pathological lesions of neurodegenerative diseases. Acta Neuropathol 96:487-494
108. Ginsberg SD, Crino PB, Hemby SE, Weingarten JA, Lee VM, Eberwine JH, Trojanowski JQ (1999) Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Ann Neurol 45:174-181
109. Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27:570-575
110. Glabe CG, Kayed R (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66:S74-S78
111. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 85:4051-4055
112. Goette A, Rocken C (2004) Atrial amyloidosis and atrial fibrillation: A gender-dependent "arrhythmogenic substrate"? Eur Heart J 25:1185-1186
113. Goldsbury CS, Cooper GJ, Goldie KN, Muller SA, SaafiEL, Gruijters WT, Misur MP, Engel A, Aebi U, Kistler J (1997) Polymorphic fibrillar assembly of human amylin. J Struct Biol 119:17-27
114. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric A b ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100:10417-10422
115. Green SL, Tolwani RJ (1999) Animal models for motor neuron disease. Lab Anim Sci 49:480-487
116. Grudzielanek S, Smirnovas V, Winter R (2007a) The effects of various membrane physicalchemical properties on the aggregation kinetics of insulin. Chem Phys Lipids 149:28-39
117. Grudzielanek S, Velkova A, Shukla A, Smirnovas V, Tatarek-Nossol M, Rehage H, Kapurniotu A, Winter R (2007b) Cytotoxicity of insulin within its self-assembly and amyloidogenic pathways. J Mol Biol 370:372-384
118. Gudiksen KL, Gitlin I, Whitesides GM (2006) Differentiation of proteins based on characteristic patterns of association and denaturation in solutions of SDS. Proc Natl Acad Sci USA 103:7968-7972
119. Guijarro JI, Sunde M, Jones JA, Campbell ID, Dobson CM (1998) Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci USA 95:4224-4228
120. Gurlo T, Ryazantsev S, Huang CJ, Yeh MW, Reber HA, Hines OJ, O'Brien TD, Glabe CG, Butler PC (2010) Evidence for proteotoxicity in b cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol 176:861-869
121. Gursky O, Aleshkov S (2000) Temperature-dependent b-sheet formation in b-amyloid A b (1-40) peptide in water: uncoupling b-structure folding from aggregation. Biochim Biophys Acta 1476:93-102
122. Guyenet SJ, Furrer SA, Damian VM, Baughan TD, La Spada AR, Garden GA (2010) A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp 39:1787. doi:10.3791/1787
123. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid b-peptide. Nat Rev Mol Cell Biol 8:101-112
124. Haataja L, Gurlo T, Huang CJ, Butler PC (2008) Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 29:303-316
125. Halliday GM, McCann H (2010) The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 1184:188-195
126. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185
127. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356
128. Harper JD, Wong SS, Lieber CM, Lansbury PT (1997) Observation of metastable A b amyloid protofibrils by atomic force microscopy. Chem Biol 4:119-125
129. Harrison RS, Sharpe PC, Singh Y, Fairlie DP (2007) Amyloid peptides and proteins in review. Rev Physiol Biochem Pharmacol 159:1-77
130. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid b-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:8876-8884
131. Hawkins PN (2003) Hereditary systemic amyloidosis with renal involvement. J Nephrol 16:443-448
132. Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR (2005) Type 2 diabetes mellitus as a conformational disease. JOP 6:287-302
133. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, Nistor M, Christie LA, Milton S, Glabe C, Barrett E, Cribbs D (2008) A two-year study with fibrillar b-amyloid (A b ) immunization in aged canines: effects on cognitive function and brain A b. J Neurosci 28:3555-3566
134. Head E, Pop V, Sarsoza F, Kayed R, Beckett TL, Studzinski CM, Tomic JL, Glabe CG, Murphy MP (2010) Amyloid b-peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J Alzheimers Dis 20:637-646
135. Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P, Kinney G, Joyce JG (2006) Solution state characterization of amyloid b-derived diffusible ligands. Biochemistry 45:15157-15167
136. Herczenik E, Gebbink MF (2008) Molecular and cellular aspects of protein misfolding and disease. FASEB J 22:2115-2133
137. Hirakura Y, Lin MC, Kagan BL (1999) Alzheimer amyloid A b 1-42 channels: effects of solvent, pH, and Congo Red. J Neurosci Res 57:458-466
138. Hirschfield GM, Hawkins PN (2003) Amyloidosis: new strategies for treatment. Int J Biochem Cell Biol 35:1608-1613
139. Hoppener JW, Ahren B, Lips CJ (2000) Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343:411-419
140. Houlden H, Crook R, Dolan RJ, McLaughlin J, Revesz T, Hardy J (2001) A novel presenilin mutation (M233V) causing very early onset Alzheimer's disease with Lewy bodies. Neurosci Lett 313:93-95
141. Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ (2008) Amyloid-b peptide (A b ) neurotoxicity is modulated by the rate of peptide aggregation: A b dimers and trimers correlate with neurotoxicity. J Neurosci 28:11950-11958
142. Ian VJM, Virginia MYL, John QT (2001) Synucleinopathies: A pathological and molecular review. Clin Neurosci Res 1:445-455
143. Ihara Y, Abraham C, Selkoe DJ (1983) Antibodies to paired helical filaments in Alzheimer's disease do not recognize normal brain proteins. Nature 304:727-730
144. Iijima K, Iijima-Ando K (2008) Drosophila models of Alzheimer's amyloidosis: the challenge of dissecting the complex mechanisms of toxicity of amyloid-b 42. J Alzheimers Dis 15:523-540
145. Iijima-Ando K, Iijima K (2010) Transgenic Drosophila models of Alzheimer's disease and tauopathies. Brain Struct Funct 214:245-262
146. Inaba S, Okada T, Konakahara T, Kodaka M (2005) Specific binding of amyloid-b-protein to IMR-32 neuroblastoma cell membrane. J Pept Res 65:485-490
147. Ingham PW (2009) The power of the zebrafish for disease analysis. Hum Mol Genet 18:R107-R112
148. Inouye H, Sharma D, Goux WJ, Kirschner DA (2006) Structure of core domain of fibril-forming PHF/Tau fragments. Biophys J 90:1774-1789
149. Inzelberg R, Polyniki A (2010) Are genetic and sporadic Parkinson's disease patients equally susceptible to develop dementia? J Neurol Sci 289:23-26
150. Jao CC, Hegde BG, Chen J, Haworth IS, Langen R (2008) Structure of membrane-bound a-synuclein from site-directed spin labeling and computational refinement. Proc Natl Acad Sci USA 105:19666-19671
151. Jayasinghe SA, Langen R (2005) Lipid membranes modulate the structure of islet amyloid polypeptide. Biochemistry 44:12113-12119
152. Jelinek R, Sheynis T (2010) Amyloid-membrane interactions: experimental approaches and techniques. Curr Protein Pept Sci 11:372-384
153. Jellinger KA (2009) Recent advances in our understanding of neurodegeneration. J Neural Transm 116:1111-1162
154. Jellinger KA (2010) Basic mechanisms of neurodegeneration: A critical update. J Cell Mol Med 14:457-487
155. Jiménez JL, Guijarro JI, Orlova E, Zurdo J, Dobson CM, Sunde M, Saibil HR (1999) Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J 18:815-821
156. Jiménez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM, Saibil HR (2002) The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci USA 99:9196-9201
157. Joachim CL, Morris JH, Kosik KS, Selkoe DJ (1987) Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders. Ann Neurol 22:514-520
158. Johnson JR, Jenn RC, Barclay JW, Burgoyne RD, Morgan A (2010) Caenorhabditis elegans: A useful tool to decipher neurodegenerative pathways. Biochem Soc Trans 38:559-563
159. Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC (2002) The channel hypothesis of Alzheimer's disease: current status. Peptides 23:1311-1315
160. Kahle PJ, Waak J, Gasser T (2009) DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 47:1354-1361
161. Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253
162. Kammerer RA, Steinmetz MO (2006) De novo design of a two-stranded coiled-coil switch peptide. J Struct Biol 155:146-153
163. Kawahara M, Kuroda Y (2000) Molecular mechanism of neurodegeneration induced by Alzheimer's b-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res Bull 53:389-397
164. Kawahara M, Arispe N, Kuroda Y, Rojas E (1997) Alzheimer's disease amyloid b-protein forms Zn 2+-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophys J 73:67-75
165. Kawooya JK, Emmons TL, Gonzalez-DeWhitt PA, Camp MC, D'Andrea SC (2003) Electrophoretic mobility of Alzheimer's amyloid-b peptides in urea-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 323:103-113
166. Kayed R, Glabe CG (2006) Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol 413:326-344
167. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489
168. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG (2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279:46363-46366
169. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C (2009) Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284:4230-4237
170. Kelly JW (1998) The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8:101-106
171. Khemtemourian L, Killian JA, Hoppener JW, Engel MF (2008) Recent insights in islet amyloid polypeptide-induced membrane disruption and its role in b-cell death in type 2 diabetes mellitus. Exp Diabetes Res 2008:421287
172. Khurana V (2008) Modeling tauopathy in the fruit fly Drosophila melanogaster. J Alzheimers Dis 15:541-553
173. Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, Grover RK, Roy R, Singh S (2005) Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol 151:229-238
174. Kim YS, Laurine E, Woods W, Lee SJ (2006) A novel mechanism of interaction between a-synuclein and biological membranes. J Mol Biol 360:386-397
175. Kim HY, Cho MK, Kumar A, Maier E, Siebenhaar C, Becker S, Fernandez CO, Lashuel HA, Benz R, Lange A, Zweckstetter M (2009) Structural properties of pore-forming oligomers of a-synuclein. J Am Chem Soc 131:17482-17489
176. Kirkitadze MD, Condron MM, Teplow DB (2001) Identification and characterization of key kinetic intermediates in amyloid b-protein fibrillogenesis. J Mol Biol 312:1103-1119
177. Kirkitadze MD, Bitan G, Teplow DB (2002) Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res 69:567-577
178. Kiss E, Keusch G, Zanetti M, Jung T, Schwarz A, Schocke M, Jaschke W, Czermak BV (2005) Dialysis-related amyloidosis revisited. AJR Am J Roentgenol 185:1460-1467
179. Kissane JM (1973) Hereditary disorders of the kidney. II. Hereditary nephropathies. Perspect Pediatr Pathol 1:147-187
180. Kitamura A, Kubota H (2010) Amyloid oligomers: dynamics and toxicity in the cytosol and nucleus. FEBS J 277:1369-1379
181. Klein WL (2002a) ADDLs & protofibrils-the missing links? Neurobiol Aging 23:231-235
182. Klein WL (2002b) A b toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41:345-352
183. Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch M, Growdon J, McLean P, Hyman BT (2006) Clinical and biochemical correlates of insoluble a-synuclein in dementia with Lewy bodies. Acta Neuropathol 111:101-108
184. Knight JD, Hebda JA, Miranker AD (2006) Conserved and cooperative assembly of membranebound a-helical states of islet amyloid polypeptide. Biochemistry 45:9496-9508
185. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL (2009) Oligomeric amyloid b associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106:4012-4017
186. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524-530
187. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau ( t ) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83:4044-4048
188. Kourie JI, Henry CL, Farrelly P (2001) Diversity of amyloid b protein fragment [1-40]-formed channels. Cell Mol Neurobiol 21:255-284
189. Kril JJ, Halliday GM (2001) Alzheimer's disease: its diagnosis and pathogenesis. Int Rev Neurobiol 48:167-217
190. Kupfer L, Hinrichs W, Groschup MH (2009) Prion protein misfolding. Curr Mol Med 9:826-835
191. Kyle RA (2001) Amyloidosis: A convoluted story. Br J Haematol 114:529-538
192. Lafaye P, Achour I, England P, Duyckaerts C, Rougeon F (2009) Single-domain antibodies recognize selectively small oligomeric forms of amyloid b, prevent A b-induced neurotoxicity and inhibit fibril formation. Mol Immunol 46:695-704
193. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from A b 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453
194. Lansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443:774-779
195. Lashuel HA, Lansbury PT Jr (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 39:167-201
196. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr (2002a) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418:291
197. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr (2002b) a-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322:1089-1102
198. Layfield R, Cavey JR, Lowe J (2003) Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2:343-356
199. Ledford H (2010) Key Alzheimer's findings questioned. Nature 466:1031
200. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM (2006) Targeting amyloid-b peptide (A b ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A b precursor protein (APP) transgenic mice. J Biol Chem 281:4292-4299
201. Lee S, Fernandez EJ, Good TA (2007) Role of aggregation conditions in structure, stability, and toxicity of intermediates in the A b fibril formation pathway. Protein Sci 16:723-732
202. Lee JK, Tran T, Tansey MG (2009) Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 4:419-429
203. Leffers KW, Schell J, Jansen K, Lucassen R, Kaimann T, Nagel-Steger L, Tatzelt J, Riesner D (2004) The structural transition of the prion protein into its pathogenic conformation is induced by unmasking hydrophobic sites. J Mol Biol 344:839-853
204. Legleiter J, Mitchell E, Lotz GP, Sapp E, Ng C, DiFiglia M, Thompson LM, Muchowski PJ (2010) Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem 285:14777-14790
205. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-b protein assembly in the brain impairs memory. Nature 440:352-357
206. LeVine H 3rd (1999) Quantification of b-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309:274-284
207. Li L, Holscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res Rev 56:384-402
208. Liao L, Cheng D, Wang J, Duong DM, Losik TG, Gearing M, Rees HD, Lah JJ, Levey AI, Peng J (2004) Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 279:37061-37068
209. Lin MC, Kagan BL (2002) Electrophysiologic properties of channels induced by A b 25-35 in planar lipid bilayers. Peptides 23:1215-1228
210. Lin H, Zhu YJ, Lal R (1999) Amyloid b protein (1-40) forms calcium-permeable, Zn 2+-sensitive channel in reconstituted lipid vesicles. Biochemistry 38:11189-11196
211. Lin H, Bhatia R, Lal R (2001) Amyloid b protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J 15:2433-2444
212. Lin CY, Gurlo T, Kayed R, Butler AE, Haataja L, Glabe CG, Butler PC (2007) Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced b-cell apoptosis in h-IAPP transgenic mice. Diabetes 56:1324-1332
213. Litvinovich SV, Brew SA, Aota S, Akiyama SK, Haudenschild C, Ingham KC (1998) Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin type III module. J Mol Biol 280:245-258
214. Looi LM (1993) Isolated atrial amyloidosis: A clinicopathologic study indicating increased prevalence in chronic heart disease. Hum Pathol 24:602-607
215. Lopez De La Paz M, Goldie K, Zurdo J, Lacroix E, Dobson CM, Hoenger A, Serrano L (2002) De novo designed peptide-based amyloid fibrils. Proc Natl Acad Sci USA 99:16052-16057
216. Lorenzo A, Yankner BA (1994) b-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 91:12243-12247
217. Lorenzo A, Razzaboni B, Weir GC, Yankner BA (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368:756-760
218. Lossi L, Cantile C, Tamagno I, Merighi A (2005) Apoptosis in the mammalian CNS: lessons from animal models. Vet J 170:52-66
219. Lu B (2009) Recent advances in using Drosophila to model neurodegenerative diseases. Apoptosis 14:1008-1020
220. Lu B, Vogel H (2009) Drosophila models of neurodegenerative diseases. Annu Rev Pathol 4:315-342
221. Lublin AL, Gandy S (2010) Amyloid-b oligomers: possible roles as key neurotoxins in Alzheimer's disease. Mt Sinai J Med 77:43-49
222. Lucin KM, Wyss-Coray T (2009) Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64:110-122
223. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J (2006) Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 116:378-385
224. Maji SK, Amsden JJ, Rothschild KJ, Condron MM, Teplow DB (2005) Conformational dynamics of amyloid b-protein assembly probed using intrinsic fluorescence. Biochemistry 44:13365-13376
225. Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, Singru PS, Nilsson KP, Simon R, Schubert D, Eisenberg D, Rivier J, Sawchenko P, Vale W, Riek R (2009a) Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 325:328-332
226. Maji SK, Wang L, Greenwald J, Riek R (2009b) Structure-activity relationship of amyloid fibrils. FEBS Lett 583:2610-2617
227. Malaga-Trillo E, Sempou E (2009) PrPs: proteins with a purpose: lessons from the zebrafish. Prion 3:129-133
228. Mallucci GR (2009) Prion neurodegeneration: starts and stops at the synapse. Prion 3:195-201
229. Marcinkiewicz M (2002) b APP and furin mRNA concentrates in immature senile plaques in the brain of Alzheimer patients. J Neuropathol Exp Neurol 61:815-829
230. Marcon G, Plakoutsi G, Canale C, Relini A, Taddei N, Dobson CM, Ramponi G, Chiti F (2005) Amyloid formation from HypF-N under conditions in which the protein is initially in its native state. J Mol Biol 347:323-335
231. Margittai M, Langen R (2006) Side chain-dependent stacking modulates tau filament structure. J Biol Chem 281:37820-37827
232. Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D'Hooge R, De Strooper B, Schymkowitz J, Rousseau F (2008) Lipids revert inert A b amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 27:224-233
233. Marzban L, Park K, Verchere CB (2003) Islet amyloid polypeptide and type 2 diabetes. Exp Gerontol 38:347-351
234. Mayeux R (2010) Clinical practice. Early Alzheimer's disease. N Engl J Med 362:2194-2201
235. McCarthy RE 3rd, Kasper EK (1998) A review of the amyloidoses that infiltrate the heart. Clin Cardiol 21:547-552
236. McDonald RJ, Craig LA, Hong NS (2010) The etiology of age-related dementia is more complicated than we think. Behav Brain Res 214:3-11
237. McGowan DP, van Roon-Mom W, Holloway H, Bates GP, Mangiarini L, Cooper GJS, Faull RLM, Snell RG (2000) Amyloid-like inclusions in Huntington's disease. Neuroscience 100:677-680
238. Meier JJ, Kayed R, Lin CY, Gurlo T, Haataja L, Jayasinghe S, Langen R, Glabe CG, Butler PC (2006) Inhibition of human IAPP fibril formation does not prevent b-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab 291:E1317-E1324
239. Merlini G, Westermark P (2004) The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 255:159-178
240. Miller Y, Ma B, Nussinov R (2010) Polymorphism in Alzheimer A b amyloid organization reflects conformational selection in a rugged energy landscape. Chem Rev 110:4820-4838
241. Miyoshi K (2009) What is 'early onset dementia'? Psychogeriatrics 9:67-72
242. Montserret R, McLeish MJ, Bockmann A, Geourjon C, Penin F (2000) Involvement of electrostatic interactions in the mechanism of peptide folding induced by sodium dodecyl sulfate binding. Biochemistry 39:8362-8373
243. Moro ML, Collins MJ, Cappellini E (2010) Alzheimer's disease and amyloid b-peptide deposition in the brain: A matter of 'aging'? Biochem Soc Trans 38:539-544
244. Moussa CE, Wersinger C, Rusnak M, Tomita Y, Sidhu A (2004) Abnormal migration of human wild-type a-synuclein upon gel electrophoresis. Neurosci Lett 371:239-243
245. Mukaetova-Ladinska EB, Xuereb JH, Garcia-Sierra F, Hurt J, Gertz HJ, Hills R, Brayne C, Huppert FA, Paykel ES, McGee MA, Jakes R, Honer WG, Harrington CR, Wischik CM (2009) Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and a-synuclein in medial temporal lobe. ScientificWorldJournal 9:1463-1475
246. Murali J, Jayakumar R (2005) Spectroscopic studies on native and protofibrillar insulin. J Struct Biol 150:180-189
247. Murray B, Lynch T, Farrell M (2005) Clinicopathological features of the tauopathies. Biochem Soc Trans 33:595-599
248. Nekooki-Machida Y, Kurosawa M, Nukina N, Ito K, Oda T, Tanaka M (2009) Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci USA 106:9679-9684
249. Nelson R, Eisenberg D (2006) Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 16:260-265
250. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, Eisenberg D (2005) Structure of the cross-b spine of amyloid-like fibrils. Nature 435:773-778
251. Novitskaya V, Bocharova OV, Bronstein I, Baskakov IV (2006) Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem 281:13828-13836
252. Nukina N, Kosik KS, Selkoe DJ (1987) Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein. Proc Natl Acad Sci USA 84:3415-3419
253. O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J, Walsh DM (2010) Amyloid b-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 30:14411-14419
254. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G (2010) Missing pieces in the Parkinson's disease puzzle. Nat Med 16:653-661
255. Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, Snyder SW, Holzman TF et al (1995) Clusterin (apoJ) alters the aggregation of amyloid b-peptide (A b 1-42) and forms slowly sedimenting A b complexes that cause oxidative stress. Exp Neurol 136:22-31
256. Okada T, Wakabayashi M, Ikeda K, Matsuzaki K (2007) Formation of toxic fibrils of Alzheimer's amyloid b-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component. J Mol Biol 371:481-489
257. Opal P, Zoghbi HY (2002) The role of chaperones in polyglutamine disease. Trends Mol Med 8:232-236
258. Pahwa R, Lyons KE (2010) Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. Am J Manag Care 16(Suppl Implications):S94-S99
259. Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, Allsop D, Hassan AH, Jensen PH, El-Agnaf OM (2009) Detection of elevated levels of soluble a-synuclein oligomers in postmortem brain extracts from patients with dementia with Lewy bodies. Brain 132:1093-1101
260. Paravastu AK, Petkova AT, Tycko R (2006) Polymorphic fibril formation by residues 10-40 of the Alzheimer's b-amyloid peptide. Biophys J 90:4618-4629
261. Paravastu AK, Leapman RD, Yau WM, Tycko R (2008) Molecular structural basis for polymorphism in Alzheimer's b-amyloid fibrils. Proc Natl Acad Sci USA 105:18349-18354
262. Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R (2009) Seeded growth of b-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci USA 106:7443-7448
263. Park J, Kim Y, Chung J (2009) Mitochondrial dysfunction and Parkinson's disease genes: insights from Drosophila. Dis Model Mech 2:336-340
264. Park GH, Kariya S, Monani UR (2010) Spinal muscular atrophy: new and emerging insights from model mice. Curr Neurol Neurosci Rep 10:108-117
265. Perl DP (2010) Neuropathology of Alzheimer's disease. Mt Sinai J Med 77:32-42
266. Peterson DW, Zhou H, Dahlquist FW, Lew J (2008) A soluble oligomer of tau associated with fiber formation analyzed by NMR. Biochemistry 47:7393-7404
267. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R (2005) Self-propagating, molecular-level polymorphism in Alzheimer's b-amyloid fibrils. Science 307:262-265
268. Petkova AT, Yau WM, Tycko R (2006) Experimental constraints on quaternary structure in Alzheimer's b-amyloid fibrils. Biochemistry 45:498-512
269. Pfister EL, Zamore PD (2009) Huntington's disease: silencing a brutal killer. Exp Neurol 220:226-229
270. Piening N, Weber P, Hogen T, Beekes M, Kretzschmar H, Giese A (2006) Photo-induced crosslinking of prion protein oligomers and prions. Amyloid 13:67-77
271. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW (1991) In vitro aging of b-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563:311-314
272. Pittock SJ, Lucchinetti CF (2007) The pathology of MS: new insights and potential clinical applications. Neurologist 13:45-56
273. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ (1995) Aggregation of secreted amyloid b-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270:9564-9570
274. Polverino de Laureto P, Taddei N, Frare E, Capanni C, Costantini S, Zurdo J, Chiti F, Dobson CM, Fontana A (2003) Protein aggregation and amyloid fibril formation by an SH3 domain probed by limited proteolysis. J Mol Biol 334:129-141
275. Porat Y, Kolusheva S, Jelinek R, Gazit E (2003) The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42:10971-10977
276. Postuma RB, Montplaisir J (2009) Predicting Parkinson's disease-why, when, and how? Parkinsonism Relat Disord 15(Suppl 3):S105-S109
277. Qin W, Chachich M, Lane M, Roth G, Bryant M, de Cabo R, Ottinger MA, Mattison J, Ingram D, Gandy S, Pasinetti GM (2006) Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys ( Saimiri sciureus ). J Alzheimers Dis 10:417-422
278. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362:329-344
279. Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R (2005) Amyloid ion channels: A common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 102:10427-10432
280. Radovan D, Smirnovas V, Winter R (2008) Effect of pressure on islet amyloid polypeptide aggregation: revealing the polymorphic nature of the fibrillation process. Biochemistry 47:6352-6360
281. Rahimi F, Bitan G (2010) Selection of aptamers for amyloid b-protein, the causative agent of Alzheimer's disease. J Vis Exp 39:1955. doi:10.3791/1955
282. Rahimi F, Shanmugam A, Bitan G (2008) Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr Alzheimer Res 5:319-341
283. Rahimi F, Murakami K, Summers JL, Chen CH, Bitan G (2009) RNA aptamers generated against oligomeric A b 40 recognize common amyloid aptatopes with low specificity but high sensitivity. PLoS One 4:e7694
284. Rangachari V, Reed DK, Moore BD, Rosenberry TL (2006) Secondary structure and interfacial aggregation of amyloid-b (1-40) on sodium dodecyl sulfate micelles. Biochemistry 45:8639-8648
285. Rangachari V, Moore BD, Reed DK, Sonoda LK, Bridges AW, Conboy E, Hartigan D, Rosenberry TL (2007) Amyloid-b (1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Biochemistry 46:12451-12462
286. Relini A, Torrassa S, Rolandi R, Gliozzi A, Rosano C, Canale C, Bolognesi M, Plakoutsi G, Bucciantini M, Chiti F, Stefani M (2004) Monitoring the process of HypF fibrillization and liposome permeabilization by protofibrils. J Mol Biol 338:943-957
287. Rhee SK, Quist AP, Lal R (1998) Amyloid b protein-(1-42) forms calcium-permeable, Zn 2+-sensitive channel. J Biol Chem 273:13379-13382
288. Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, Roessner A, Goette A (2002) Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 106:2091-2097
289. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid b-protein assembly and Alzheimer disease. J Biol Chem 284:4749-4753
290. Rozas JL, Gomez-Sanchez L, Tomas-Zapico C, Lucas JJ, Fernandez-Chacon R (2010) Presynaptic dysfunction in Huntington's disease. Biochem Soc Trans 38:488-492
291. Ryan TM, Howlett GJ, Bailey MF (2008) Fluorescence detection of a lipid-induced tetrameric intermediate in amyloid fibril formation by apolipoprotein C-II. J Biol Chem 283:35118-35128
292. Sager JJ, Bai Q, Burton EA (2010) Transgenic zebrafish models of neurodegenerative diseases. Brain Struct Funct 214:285-302
293. Sahara N, Maeda S, Takashima A (2008) Tau oligomerization: A role for tau aggregation intermediates linked to neurodegeneration. Curr Alzheimer Res 5:591-598
294. Saiki M, Honda S, Kawasaki K, Zhou D, Kaito A, Konakahara T, Morii H (2005) Higher-order molecular packing in amyloid-like fibrils constructed with linear arrangements of hydrophobic and hydrogen-bonding side-chains. J Mol Biol 348:983-998
295. Sakono M, Zako T (2010) Amyloid oligomers: formation and toxicity of A b oligomers. FEBS J 277:1348-1358
296. Sanchorawala V (2006) Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 1:1331-1341
297. Sanderson KL, Butler L, Ingram VM (1997) Aggregates of a b-amyloid peptide are required to induce calcium currents in neuron-like human teratocarcinoma cells: relation to Alzheimer's disease. Brain Res 744:7-14
298. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A (2009) Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 219:385-397
299. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJ, McFarlane HT, Madsen AO, Riekel C, Eisenberg D (2007) Atomic structures of amyloid cross-b spines reveal varied steric zippers. Nature 447:453-457
300. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549-558
301. Scheuner D, Kaufman RJ (2008) The unfolded protein response: A pathway that links insulin demand with b-cell failure and diabetes. Endocr Rev 29:317-333
302. Schiesling C, Kieper N, Seidel K, Kruger R (2008) Review: familial Parkinson's disease- genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol Appl Neurobiol 34:255-271
303. Schleiden MJ (1838) Beiträge zur phytogenesis. Arch Anat Physiol Wiss Med 13:137-176
304. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S (2010) A pathologic cascade leading to synaptic dysfunction in a-synuclein-induced neurodegeneration. J Neurosci 30:8083-8095
305. Serpell LC (2000) Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 1502:16-30
306. Serpell LC, Sunde M, Benson MD, Tennent GA, Pepys MB, Fraser PE (2000) The protofilament substructure of amyloid fibrils. J Mol Biol 300:1033-1039
307. Sesti F, Liu S, Cai SQ (2010) Oxidation of potassium channels by ROS: A general mechanism of aging and neurodegeneration? Trends Cell Biol 20:45-51
308. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-b protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:2866-2875
309. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837-842
310. Sharma S, Mukherjee M, Kedage V, Muttigi MS, Rao A, Rao S (2009) Sporadic Creutzfeldt-Jakob disease-a review. Int J Neurosci 119:1981-1994
311. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ (2003) The formation of highly soluble oligomers of a-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37:583-595
312. Shepherd CE, Goyette J, Utter V, Rahimi F, Yang Z, Geczy CL, Halliday GM (2006) Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease. Neurobiol Aging 27:1554-1563
313. Shulman LM (2010) Understanding disability in Parkinson's disease. Mov Disord 25 (Suppl 1):S131-S135
314. Simoneau S, Rezaei H, Sales N, Kaiser-Schulz G, Lefebvre-Roque M, Vidal C, Fournier JG, Comte J, Wopfner F, Grosclaude J, Schatzl H, Lasmezas CI (2007) In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog 3:e125
315. Sipe JD, Cohen AS (2000) Review: history of the amyloid fibril. J Struct Biol 130:88-98
316. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P (2010) Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 17:101-104
317. Skovronsky DM, Lee VM, Trojanowski JQ (2006) Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1:151-170
318. Sokolov Y, Kozak JA, Kayed R, Chanturiya A, Glabe C, Hall JE (2006) Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol 128:637-647
319. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE (2009) Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 19:392-398
320. Sorgjerd K, Klingstedt T, Lindgren M, Kagedal K, Hammarstrom P (2008) Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem Biophys Res Commun 377:1072-1078
321. Steensma DP, Kyle RA (2007) A history of the kidney in plasma cell disorders. Contrib Nephrol 153:5-24
322. Stefani M, Dobson CM (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81:678-699
323. Steiner B, Mandelkow EM, Biernat J, Gustke N, Meyer HE, Schmidt B, Mieskes G, Soling HD, Drechsel D, Kirschner MW et al (1990) Phosphorylation of microtubule-associated protein tau: identification of the site for Ca 2+-calmodulin dependent kinase and relationship with tau phosphorylation in Alzheimer tangles. EMBO J 9:3539-3544
324. Sugama S, Takenouchi T, Cho BP, Joh TH, Hashimoto M, Kitani H (2009) Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. Inflamm Allergy Drug Targets 8:277-284
325. Sunde M, Blake C (1997) The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 50:123-159
326. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC (1997) Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 273:729-739
327. Surguchev A, Surguchov A (2010) Conformational diseases: looking into the eyes. Brain Res Bull 81:12-24
328. Swift B (2002) Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet Med 19:881-882
329. Taddei K, Kwok JB, Kril JJ, Halliday GM, Creasey H, Hallupp M, Fisher C, Brooks WS, Chung C, Andrews C, Masters CL, Schofield PR, Martins RN (1998) Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease. Neuroreport 9:3335-3339
330. Takahashi T, Tada K, Mihara H (2009) RNA aptamers selected against amyloid b-peptide (A b ) inhibit the aggregation of A b. Mol Biosyst 5:986-991
331. Takeda A, Hasegawa T, Matsuzaki-Kobayashi M, Sugeno N, Kikuchi A, Itoyama Y, Furukawa K (2006) Mechanisms of neuronal death in synucleinopathy. J Biomed Biotechnol 2006:19365
332. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510-518
333. Tartaglia GG, Pawar AP, Campioni S, Dobson CM, Chiti F, Vendruscolo M (2008) Prediction of aggregation-prone regions in structured proteins. J Mol Biol 380:425-436
334. Taylor TN, Greene JG, Miller GW (2010) Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res 211:1-10
335. Teplow DB (1998) Structural and kinetic features of amyloid b-protein fibrillogenesis. Amyloid 5:121-142
336. Tjernberg L, Hosia W, Bark N, Thyberg J, Johansson J (2002) Charge attraction and b propensity are necessary for amyloid fibril formation from tetrapeptides. J Biol Chem 277:43243-43246
337. Tompa P (2002) Intrinsically unstructured proteins. Trends Biochem Sci 27:527-533
338. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006) Effects of secreted oligomers of amyloid b-protein on hippocampal synaptic plasticity: A potent role for trimers. J Physiol 572:477-492
339. Trexler AJ, Rhoades E (2009) a-Synuclein binds large unilamellar vesicles as an extended helix. Biochemistry 48:2304-2306
340. Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E (2007) Dynamics of a-synuclein aggregation and inhibition of pore-like oligomer development by b-synuclein. FEBS J 274:1862-1877
341. Tsukakoshi K, Harada R, Sode K, Ikebukuro K (2010) Screening of DNA aptamer which binds to a-synuclein. Biotechnol Lett 32:643-648
342. Tycko R, Sciarretta KL, Orgel JP, Meredith SC (2009) Evidence for novel b-sheet structures in Iowa mutant b-amyloid fibrils. Biochemistry 48:6072-6084
343. van Ham TJ, Breitling R, Swertz MA, Nollen EA (2009) Neurodegenerative diseases: lessons from genome-wide screens in small model organisms. EMBO Mol Med 1:360-370
344. Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW (2001) Pathogenic effects of D23N Iowa mutant amyloid b-protein. J Biol Chem 276:32860-32866
345. van Rooijen BD, Claessens MM, Subramaniam V (2010) Membrane interactions of oligomeric a-synuclein: potential role in Parkinson's disease. Curr Protein Pept Sci 11:334-342
346. Varkey J, Isas JM, Mizuno N, Jensen MB, Bhatia VK, Jao CC, Petrlova J, Voss JC, Stamou DG, Steven AC, Langen R (2010) Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J Biol Chem 285:32486-32493
347. Vasilevko V, Head E (2009) Immunotherapy in a natural model of A b pathogenesis: the aging beagle. CNS Neurol Disord Drug Targets 8:98-113
348. Vasilevko V, Pop V, Kim HJ, Saing T, Glabe CC, Milton S, Barrett EG, Cotman CW, Cribbs DH, Head E (2010) Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated A b. Neurobiol Dis 39:301-310
349. Virchow R (1854a) Über den Gang der amyloiden degeneration. Archiv für pathologische Anatomie und Physiologie und für klinische Medicin 8:364-368
350. Virchow R (1854b) Ueber eine im Gehirn und Rückenmark des Menschen aufgefundene Substanz mit der chemsichen Reaction der Cellulose. Virchows Arch 6:135-138
351. Volles MJ, Lansbury PT Jr (2002) Vesicle permeabilization by protofibrillar a-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41:4595-4602
352. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr (2001) Vesicle permeabilization by protofibrillar a-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40:7812-7819
353. von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, Mandelkow E (2001) Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local b-structure. J Biol Chem 276:48165-48174
354. Walker LC (1997) Animal models of cerebral b-amyloid angiopathy. Brain Res Brain Res Rev 25:70-84
355. Walker LC, Levine H 3rd, Mattson MP, Jucker M (2006) Inducible proteopathies. Trends Neurosci 29:438-443
356. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB (1997) Amyloid b-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272:22364-22372
357. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB (1999) Amyloid b-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274:25945-25952
358. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal longterm potentiation in vivo. Nature 416:535-539
359. Wang LH, Qin ZH (2006) Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies. Acta Pharmacol Sin 27:1287-1302
360. Wang C, Huang L, Wang L, Hong Y, Sha Y (2007) One-dimensional self-assembly of a rational designed b-structure peptide. Biopolymers 86:23-31
361. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23:425-428
362. Westermark P, Wilander E (1978) The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15:417-421
363. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD (2007) A primer of amyloid nomenclature. Amyloid 14:179-183
364. Wetzel R (2006) Amyloid fibrils-common threads in the natural history of proteins. Acc Chem Res 39:567
365. Wetzel R, Shivaprasad S, Williams AD (2007) Plasticity of amyloid fibrils. Biochemistry 46:1-10
366. White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ (2005) Differential effects of oligomeric and fibrillar amyloid-b 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 18:459-465
367. Woodruff-Pak DS (2008) Animal models of Alzheimer's disease: therapeutic implications. J Alzheimers Dis 15:507-521
368. Xia W, Zhang J, Kholodenko D, Citron M, Podlisny MB, Teplow DB, Haass C, Seubert P, Koo EH, Selkoe DJ (1997) Enhanced production and oligomerization of the 42-residue amyloid b-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem 272:7977-7982
369. Yamamoto S, Hasegawa K, Yamaguchi I, Tsutsumi S, Kardos J, Goto Y, Gejyo F, Naiki H (2004) Low concentrations of sodium dodecyl sulfate induce the extension of b 2-microglobulinrelated amyloid fibrils at a neutral pH. Biochemistry 43:11075-11082
370. Yamamoto S, Kazama JJ, Narita I, Naiki H, Gejyo F (2009) Recent progress in understanding dialysis-related amyloidosis. Bone 45(Suppl 1):S39-S42
371. Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW (2008) Towards a transgenic model of Huntington's disease in a non-human primate. Nature 453:921-924
372. Ylera F, Lurz R, Erdmann VA, Furste JP (2002) Selection of RNA aptamers to the Alzheimer's disease amyloid peptide. Biochem Biophys Res Commun 290:1583-1588
373. Yoshiike Y, Akagi T, Takashima A (2007) Surface structure of amyloid-b fibrils contributes to cytotoxicity. Biochemistry 46:9805-9812
374. Zakharov SD, Hulleman JD, Dutseva EA, Antonenko YN, Rochet JC, Cramer WA (2007) Helical a-synuclein forms highly conductive ion channels. Biochemistry 46:14369-14379
375. Zanuy D, Nussinov R (2003) The sequence dependence of fiber organization. A comparative molecular dynamics study of the islet amyloid polypeptide segments 22-27 and 22-29. J Mol Biol 329:565-584
376. Zhang Q, Powers ET, Nieva J, Huff ME, Dendle MA, Bieschke J, Glabe CG, Eschenmoser A, Wentworth P Jr, Lerner RA, Kelly JW (2004) Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci USA 101:4752-4757
377. Zurdo J, Guijarro JI, Dobson CM (2001a) Preparation and characterization of purified amyloid fibrils. J Am Chem Soc 123:8141-8142
378. Zurdo J, Guijarro JI, Jimenez JL, Saibil HR, Dobson CM (2001b) Dependence on solution conditions of aggregation and amyloid formation by an SH3 domain. J Mol Biol 311:325-340